Ryan Price

Associate Professor

University of Utah
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Ryan Price is an Assistant Professor at the University of Utah, USA. His research areas include proton therapy, with a focus on automation frameworks for online reviews of dose distributions and the verification of surface-guided radiation therapy alignment. Additionally, he investigates the efficacy of DirectSPR images for treatment planning and measures fetal doses using advanced proton therapy systems.

Articles (5)

Background The adoption of HyperSight CBCT has become widespread due to its rapid CBCT scan acquisition (< 6 s) and superior image quality. Numerous studies have been conducted to evaluate HyperSight CBCT's image quality and the accuracy of treatment planning dose calculations using HyperSight CBCT. Nevertheless, for the main function of CBCT as a tool of image guided radiation therapy (IGRT), one clinically significant question remains unanswered: What is the quantitative correlation between exposure level (mAs) and desired image quality? This study aims to explore the quantitative correlation between exposure level and image quality, providing guidelines for selecting the appropriate CBCT mAs based on imaging objectives and patient size for the optimal IGRT alignment. Purpose To investigate the correlation between HyperSight CBCT (equipped on Halcyon linear accelerator) exposure level and image quality. Methods Nine‐series of 261 sets CBCT scans were acquired using HyperSight on the Halcyon (125 kV, 133‐971 mAs, FOV: 28.2, 36, and 53.8 cm). Three‐series were acquired with the CatPhan 604 alone, three‐series with CatPhan 604 surrounded by a 32 cm custom‐made acrylic annulus, and three series with CatPhan 604 surrounded by a 40 cm custom‐made acrylic annulus. Image quality metrics were analyzed included signal‐to‐noise ratio (SNR), contrast‐to‐noise ratio (CNR), image noise, low‐contrast visibility (LCV), uniformity index (UI), integral non‐uniformity (INU), and modulation transfer function (MTF). The correlation between mAs and image quality was evaluated. Results The SNR and CNR for all material inserts increased with rising mAs for all scans, with a higher amplitude of increase for scans without annuli. The SNR and CNR were higher for scans without annuli. Both image noise and LCV decreased with rising mAs and were higher for scans with annuli. The UI was independent of mAs for scans of CatPhan alone and CatPhan with a small annulus, and was slightly higher for scans without annuli (∼0.1 vs ∼0.2). The INU slightly increased with rising mAs and was higher for scans without annuli. MTF was independent of mAs and with or without annuli. MTF values varied with FOV, with smaller FOV yielding better image sharpness. All parameters were FOV‐dependent except INU, and generally, the larger the FOV, the better the image quality (except spatial resolution). Conclusions HyperSight CBCT acquisition is recommended to be performed with a maximum FOV of 53.8 cm. To meet the Rose criterion, for a 20 cm width object, CBCT should be acquired at ≥154 mAs; for a 32 cm width object, CBCT should be acquired at ≥572.6 mAs to reach a 3σ confidence level; for a 40 cm object, CBCT should be acquired at ≥572.6 mAs to reach a 3σ confidence level for all materials except polystyrene (soft‐tissue).

Year:

2025

Year:

2024

Background Surface‐guided radiation therapy (SGRT) systems have been widely installed and utilized on linear accelerators. However, the use of SGRT with proton therapy is still a newly developing field, and published reports are currently very limited. Purpose To assess the clinical application and alignment agreement of SGRT with CT‐on‐rails (CTOR) and kV‐2D image‐guided radiation therapy (IGRT) for breast treatment using proton therapy. Methods Four patients receiving breast or chest wall treatment with proton therapy were the subjects of this study. Patient #1′s IGRT modalities were a combination of kV‐2D and CTOR. CTOR was the only imaging modality for patients #2 and #3, and kV‐2D was the only imaging modality for patient #4. The patients’ respiratory motions were assessed using a 2‐min surface position recorded by the SGRT system during treatment. SGRT offsets reported after IGRT shifts were recorded for each fraction of treatment. The agreement between SGRT and either kV‐2D or CTOR was evaluated. Results The respiratory motion amplitude was <4 mm in translation and <2.0 ° in rotation for all patients. The mean and maximum amplitude of SGRT offsets after application of IGRT shifts were ≤(2.6 mm, 1.6 ° ) and (6.8 mm, 4.5 ° ) relative to kV‐2D‐based IGRT; ≤(3.0 mm, 2.6 ° ) and (5.0 mm, 4.7 ° ) relative to CTOR‐based IGRT without breast tissue inflammation. For patient #3, breast inflammation was observed for the last three fractions of treatment, and the maximum SGRT offsets post CTOR shifts were up to (14.0 mm, 5.2 ° ). Conclusions Due to the overall agreement between SGRT and IGRT within reasonable tolerance, SGRT has the potential to serve as a valuable auxiliary IGRT tool for proton breast treatment and may improve the efficiency of proton breast treatment.

Year:

2024

Year:

2023

Year:

2023

Collaborators (1)

Jeremy Kunz

Assistant Professor

University of Utah Health Huntsman Cancer Institute

UNITED STATES
View details